MedTrace Logo

An Extension Study of PEAK Trial

NCT02763007 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2019-06-05

No results posted yet for this study

Summary

Double blind, three arm, comparative intervention trial for 24 weeks(PEAK study) with open label extension trial for 28 weeks followed by 2 year observational study.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

alogliptin+pioglitazone

alogliptin and pioglitazone add on metformin

DRUG

alogliptin

nesina add on metformin

DRUG

pioglitazone

actos add on metformin

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Kun-Ho Yoon

    lead OTHER

Principal Investigators

  • Kun-Ho Yoon, MD, PhD · Seoul St Mary's Hospital, The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-18
Primary Completion
2018-12-19
Completion
2019-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02763007 on ClinicalTrials.gov